What are the indications of treating PH in COPD with Pharmacotherapy?
Posted: 02 Feb 2017, 20:22
There are few available options for treating Pulmonary hypertension in COPD and this statement may help a better understanding.
"Long-term supplemental oxygen remains the primary treatment in COPD patients with PH. The administration of new vasodilators (prostanoids, endothelin-1 receptor antagonists and phosphodiesterase-5 inhibitors) dedicated to idiopathic pulmonary arterial hypertension in the disproportionate subgroup of patients with "out-of-proportion" PH may be considered in the setting of clinical trials. The use of these drugs in COPD patients with PH < 40 mmHg may worsen gas exchange, and to date, has no proven benefit.
Further novel agents under review/trials are "5-HT receptor antagonists, Rho-kinase inhibitors, statins and stem cell therapy.
Reference:Curr Drug Targets. 2011 Apr;12(4):501-13.
Pulmonary hypertension in COPD: pathophysiology and therapeutic targets.
Zakynthinos E1, Daniil Z, Papanikolaou J, Makris D.
"Long-term supplemental oxygen remains the primary treatment in COPD patients with PH. The administration of new vasodilators (prostanoids, endothelin-1 receptor antagonists and phosphodiesterase-5 inhibitors) dedicated to idiopathic pulmonary arterial hypertension in the disproportionate subgroup of patients with "out-of-proportion" PH may be considered in the setting of clinical trials. The use of these drugs in COPD patients with PH < 40 mmHg may worsen gas exchange, and to date, has no proven benefit.
Further novel agents under review/trials are "5-HT receptor antagonists, Rho-kinase inhibitors, statins and stem cell therapy.
Reference:Curr Drug Targets. 2011 Apr;12(4):501-13.
Pulmonary hypertension in COPD: pathophysiology and therapeutic targets.
Zakynthinos E1, Daniil Z, Papanikolaou J, Makris D.